Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Men aged 18 years or older
• People who have a confirmed diagnosis of prostate cancer (adenocarcinoma type), with less than 10% of a specific cell type called neuroendocrine cells, and no small cell component
• People whose prostate cancer has spread to other parts of the body (metastatic) and is no longer responding to treatments that lower testosterone (castration-resistant)
• People whose cancer spread is visible on standard scans such as CT scans, MRI, or bone scans (cancer visible only on a specific type of scan called PSMA PET will not count for joining purposes)
• People whose cancer is continuing to grow, shown by rising PSA blood test results, growth in soft tissue tumours, or new or growing areas of cancer on bone scans
• People who are still receiving hormone therapy to lower testosterone (such as LHRH injections), unless surgical removal of the testicles has already been performed
• People with a good general health status, rated 0 or 1 on a standard medical scale (confirm with trial site)
• People whose cancer got worse while being treated with one of a group of newer hormone-blocking medicines (such as abiraterone, enzalutamide, apalutamide, or darolutamide)
• People who finished that hormone-blocking medicine at least 4 weeks before starting the trial
• People who have had enough time since their last cancer treatment or surgery, with most side effects from those treatments having resolved
• People with adequate functioning of bone marrow, liver, kidneys, and blood clotting (confirm with trial site)

Who may not be able to join:

• People who have had another type of cancer, unless it was a non-melanoma skin cancer or another cancer that was fully treated with no signs of return for at least 3 years
• People whose prostate cancer includes a small cell component or has 10% or more neuroendocrine type cells
• People who have previously been treated with a specific group of targeted medicines that affect pathways called PI3K, AKT, or mTOR (confirm with trial site)
• People who have had chemotherapy or radioactive drug treatments specifically for castration-resistant prostate cancer (some earlier chemotherapy treatments for hormone-sensitive prostate cancer may still be acceptable — confirm with trial site)
• People with uncontrolled type 1 or type 2 diabetes
• People with active or untreated cancer that has spread to the brain or the lining around the brain, unless it was previously treated, is stable, and meets specific conditions (confirm with trial site)
• People with a significant history of heart or cardiovascular problems
• People with digestive system conditions that would prevent oral medication from being properly absorbed, or a history of inflammatory bowel disease
• People who are unable to swallow tablets or capsules

Important: Always verify eligibility with the trial site directly before applying.